|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
189,490,000 |
Market
Cap: |
1.51(B) |
Last
Volume: |
1,754,233 |
Avg
Vol: |
4,315,920 |
52
Week Range: |
$4.13 - $8.69 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 1115 |
Guru Rank Value : 0 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile BioCryst Pharmaceuticals is a commercial-stage biotechnology company that discovers oral, small-molecule medicines. Co. focuses on oral treatments for rare diseases. Co.'s drug/drug candidates include: ORLADEYO (berotralstat), an oral serine protease inhibitor targeting kallikrein that is being developed for the prevention of Hereditary Angioedema attacks; BCX9930, an oral factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors for the treatment of fibrodysplasia ossificans progressive; and RAPIVAB® (peramivir injection), an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
183,601 |
183,601 |
183,601 |
Total Buy Value |
$0 |
$1,048,338 |
$1,048,338 |
$1,048,338 |
Total People Bought |
0 |
10 |
10 |
10 |
Total Buy Transactions |
0 |
10 |
10 |
10 |
Total Shares Sold |
0 |
11,387 |
11,387 |
506,586 |
Total Sell Value |
$0 |
$69,059 |
$69,059 |
$6,068,300 |
Total People Sold |
0 |
2 |
2 |
10 |
Total Sell Transactions |
0 |
2 |
2 |
16 |
End Date |
2024-06-23 |
2024-03-22 |
2023-09-22 |
2022-09-22 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Staab Thomas R Ii |
Senior Vice President and CFO |
|
2017-03-16 |
4 |
D |
$8.80 |
$108,310 |
D/D |
(12,308) |
141,460 |
|
- |
|
Staab Thomas R Ii |
Senior Vice President and CFO |
|
2017-03-16 |
4 |
OE |
$1.42 |
$108,300 |
D/D |
36,455 |
153,768 |
|
- |
|
Staab Thomas R Ii |
Senior Vice President and CFO |
|
2017-03-10 |
4 |
AS |
$9.06 |
$29,445 |
D/D |
(3,250) |
117,313 |
|
- |
|
Staab Thomas R Ii |
Senior Vice President and CFO |
|
2017-03-10 |
4 |
OE |
$3.78 |
$12,285 |
D/D |
3,250 |
120,563 |
|
- |
|
Staab Thomas R Ii |
Senior Vice President and CFO |
|
2017-03-08 |
4 |
AS |
$8.20 |
$54,763 |
D/D |
(6,500) |
117,313 |
|
- |
|
Staab Thomas R Ii |
Senior Vice President and CFO |
|
2017-03-08 |
4 |
OE |
$3.78 |
$24,570 |
D/D |
6,500 |
123,813 |
|
- |
|
Staab Thomas R Ii |
Senior Vice President and CFO |
|
2017-03-06 |
4 |
AS |
$7.90 |
$25,675 |
D/D |
(3,250) |
117,313 |
|
- |
|
Staab Thomas R Ii |
Senior Vice President and CFO |
|
2017-03-06 |
4 |
OE |
$3.78 |
$12,285 |
D/D |
3,250 |
120,563 |
|
- |
|
Ingram Robert Alexander |
Director |
|
2017-03-02 |
4 |
A |
$6.24 |
$9,996 |
D/D |
1,602 |
5,823 |
|
- |
|
Hutson Nancy J |
Director |
|
2017-03-01 |
4 |
A |
$6.24 |
$9,996 |
D/D |
1,602 |
30,266 |
|
- |
|
Cohen Fred E |
Director |
|
2017-03-01 |
4 |
A |
$6.24 |
$9,996 |
D/D |
1,602 |
117,469 |
|
- |
|
Babu Yarlagadda S |
Senior VP - Drug Discovery |
|
2017-01-20 |
4 |
D |
$5.95 |
$30,244 |
D/D |
(5,083) |
104,706 |
|
- |
|
Barnes Alane P |
VP, General Counsel & Corp Sec |
|
2017-01-20 |
4 |
D |
$5.95 |
$15,464 |
D/D |
(2,599) |
75,497 |
|
- |
|
Staab Thomas R Ii |
Senior Vice President and CFO |
|
2017-01-20 |
4 |
D |
$5.95 |
$30,928 |
D/D |
(5,198) |
117,313 |
|
- |
|
Sheridan William P |
Senior VP - CMO |
|
2017-01-20 |
4 |
D |
$5.95 |
$34,278 |
D/D |
(5,761) |
82,916 |
|
- |
|
Stonehouse Jon P |
President & CEO |
|
2017-01-20 |
4 |
D |
$5.95 |
$62,903 |
D/D |
(10,572) |
645,418 |
|
- |
|
Babu Yarlagadda S |
Senior VP - Drug Discovery |
|
2017-01-01 |
4 |
D |
$6.33 |
$10,375 |
D/D |
(1,639) |
109,789 |
|
- |
|
Barnes Alane P |
VP, General Counsel & Corp Sec |
|
2017-01-01 |
4 |
D |
$6.33 |
$8,109 |
D/D |
(1,281) |
78,096 |
|
- |
|
Sheridan William P |
Senior VP - CMO |
|
2017-01-01 |
4 |
D |
$6.33 |
$13,173 |
D/D |
(2,081) |
88,677 |
|
- |
|
Staab Thomas R Ii |
Senior Vice President and CFO |
|
2017-01-01 |
4 |
D |
$6.33 |
$10,609 |
D/D |
(1,676) |
122,511 |
|
- |
|
Stonehouse Jon P |
President & CEO |
|
2017-01-01 |
4 |
D |
$6.33 |
$54,406 |
D/D |
(8,595) |
655,990 |
|
- |
|
Staab Thomas R Ii |
Senior Vice President and CFO |
|
2016-12-19 |
4 |
AS |
$7.45 |
$24,213 |
D/D |
(3,250) |
124,187 |
|
- |
|
Staab Thomas R Ii |
Senior Vice President and CFO |
|
2016-12-19 |
4 |
OE |
$3.78 |
$12,285 |
D/D |
3,250 |
127,437 |
|
- |
|
Ingram Robert Alexander |
Director |
|
2016-12-01 |
4 |
A |
$5.59 |
$9,995 |
D/D |
1,788 |
4,221 |
|
- |
|
Hutson Nancy J |
Director |
|
2016-12-01 |
4 |
A |
$5.59 |
$9,995 |
D/D |
1,788 |
28,664 |
|
- |
|
755 Records found
|
|
Page 15 of 31 |
|
|